The short version of Lactam bridge fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-14. Anything still debated is marked as such rather than presented as settled.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
== Genetics == AGAT deficiency is caused by deficient activity of arginine:glycine amidinotransferase, which is coded for by GATM, located on the long arm of chromosome 15. AGAT deficiency is inherited in an autosomal recessive manner, which means pathogenic variants must be inherited from each parent. This enzyme catalyzes the first step in creatine biosynthesis, the combination of arginine and glycine to form guanidinoacetate, which also results in the formation or ornithine as a by product. These reactions take place primarily in the kidney and pancreas. The clinical manifestations of AGAT deficiency are caused by the decreased amounts of creatine produced.
The three substrates of this enzyme are D-ribose, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are D-ribonic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-ribose:NADP+ 1-oxidoreductase. Other names in common use include D-ribose dehydrogenase (NADP+), NADP+-pentose-dehydrogenase, and ribose 1-dehydrogenase (NADP+).
== Function == Msr is ubiquitous and highly conserved. Human and animal studies have shown the highest levels of expression in kidney and liver. It carries out the enzymatic reduction of methionine sulfoxide (MetO), the oxidized form of the amino acid methionine (Met), back to methionine, using thioredoxin to catalyze the enzymatic reduction and repair of oxidized methionine residues. Its proposed function is thus the repair of oxidative damage to proteins to restore biological activity. Oxidation of methionine residues in tissue proteins can cause them to misfold or otherwise render them dysfunctional.
Sources: en.wikipedia.org
Deoxyribozymes, also called DNAzymes or catalytic DNA, were first discovered in 1994. They are mostly single stranded DNA sequences isolated from a large pool of random DNA sequences through a combinatorial approach called in vitro selection or systematic evolution of ligands by exponential enrichment (SELEX). DNAzymes catalyze variety of chemical reactions including RNA-DNA cleavage, RNA-DNA ligation, amino acids phosphorylation-dephosphorylation, carbon-carbon bond formation, etc. DNAzymes can enhance catalytic rate of chemical reactions up to 100,000,000,000-fold over the uncatalyzed reaction. The most extensively studied class of DNAzymes is RNA-cleaving types which have been used to detect different metal ions and designing therapeutic agents. Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme (lead-specific), the CA1-3 DNAzymes (copper-specific), the 39E DNAzyme (uranyl-specific) and the NaA43 DNAzyme (sodium-specific). The NaA43 DNAzyme, which is reported to be more than 10,000-fold selective for sodium over other metal ions, was used to make a real-time sodium sensor in cells.
If Gaddafi's Free Officers had not preempted the Shelhis, they would have almost certainly been defeated by the combined forces of Abdul Aziz Shelhi, the deputy commander of Libya's army, and the prominent families in Cyrenaica that supported the Shelhi family. On 1 September, Gaddafi's Free Officers occupied airports, police depots, radio stations, and government offices in Tripoli and Benghazi. Gaddafi took control of the Berka barracks in Benghazi, while Umar Muhayshi occupied Tripoli barracks and Jalloud seized the city's anti-aircraft batteries. Khweldi Hameidi took over the Tripoli radio station and arrested crown prince Sayyid Hasan ar-Rida al-Mahdi as-Sanussi, forcing him to relinquish his claim to the throne. They met no serious resistance and wielded little violence against the monarchists. Once Gaddafi removed the government, he announced the foundation of the Libyan Arab Republic. Addressing the populace by radio, he proclaimed an end to the "reactionary and corrupt" regime, "the stench of which has sickened and horrified us all". Due to the coup's bloodless nature, it was initially labelled the "White Revolution", although was later renamed the "One September Revolution" after its date. Gaddafi insisted that the Free Officers' coup represented a revolution, marking the start of widespread change in the socio-economic and political nature of Libya. He proclaimed that the revolution meant "freedom, socialism, and unity", and soon implemented measures to achieve this.
Yawn and swallow during ascent and descent Use the Valsalva maneuver during ascent and descent Avoid sleeping during takeoffs and landings Use an over the counter nasal spray Using filtered earplugs which slowly equalize the pressure against the eardrum during ascents and descents Outside of a pressurized cabin environment at very high altitudes, a pressure suit is the usual protective measure and is the definitive protection in decompression and exposure to vacuum, but they are expensive, heavy, bulky, restrict mobility, cause thermal regulatory problems, and reduce comfort. To prevent injury from unavoidable pressure changes, similar equalization techniques and relatively slow pressure changes are required, which in turn require patent Eustachian tubes and sinuses.
The application claims methods of designing CNTF analogues with lower immunogenicity than Axokine based on analysis of affinity of each modified epitope for each of 52 class II MHC alleles, and provides specific examples of such modifications. No such analogues are currently listed in Xencor's product pipeline.
Sources: en.wikipedia.org
As of 2019, AAV vectors have been used in over 250 clinical trials worldwide, approximately 8.3% of virus-vectored gene-therapy trials. Recently, promising results have been obtained from Phase 1 and Phase 2 trials for a number of diseases, including Leber's congenital amaurosis, hemophilia, congestive heart failure, spinal muscular atrophy, lipoprotein lipase deficiency, and Parkinson's disease. AAV based gene therapy products have entered the worldwide market following completion of successful clinical trials. The table below contains FDA approved gene therapies that have entered the American Market and possibly other markets.
Deoxyribozymes, also called DNAzymes or catalytic DNA, were first discovered in 1994. They are mostly single stranded DNA sequences isolated from a large pool of random DNA sequences through a combinatorial approach called in vitro selection or systematic evolution of ligands by exponential enrichment (SELEX). DNAzymes catalyze variety of chemical reactions including RNA-DNA cleavage, RNA-DNA ligation, amino acids phosphorylation-dephosphorylation, carbon-carbon bond formation, etc. DNAzymes can enhance catalytic rate of chemical reactions up to 100,000,000,000-fold over the uncatalyzed reaction. The most extensively studied class of DNAzymes is RNA-cleaving types which have been used to detect different metal ions and designing therapeutic agents. Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme (lead-specific), the CA1-3 DNAzymes (copper-specific), the 39E DNAzyme (uranyl-specific) and the NaA43 DNAzyme (sodium-specific). The NaA43 DNAzyme, which is reported to be more than 10,000-fold selective for sodium over other metal ions, was used to make a real-time sodium sensor in cells.
The assay has a very good sensitivity (detection limit for 17β-estradiol in the YES assay about 5 × 10−12 M or 1.4 ng/L), and the microplate format requires only small amounts of sample. Analysis of native aqueous samples, concentrated environmental samples and chemicals or mixtures in solvents like ethanol or DMSO is possible. Results can be obtained as quickly as after an overnight exposure. The handling of yeast cells is generally less demanding than mammalian cell culture. No international standards are available to date. An ISO guideline for the YES assay is under preparation. Saliva hormone testing
Bismuth has few commercial applications, and those that use it generally require small quantities relative to other raw materials. In the United States, for example, 733 tonnes of bismuth were consumed in 2016, of which 70% went into chemicals (including pharmaceuticals, pigments, and cosmetics) and 11% into bismuth alloys.
Rosiglitazone is a member of the thiazolidinedione class of drugs. Thiazolidinediones act as insulin sensitizers. They reduce glucose, fatty acid, and insulin blood concentrations. They work by binding to the peroxisome proliferator-activated receptors (PPARs). PPARs are transcription factors that reside in the nucleus and become activated by ligands such as thiazolidinediones. Thiazolidinediones enter the cell, bind to the nuclear receptors, and alter the expression of genes. The several PPARs include PPARα, PPARβ/δ, and PPARγ. Thiazolidinediones bind to PPARγ. PPARs are expressed in fat cells, cells of the liver, muscle, heart, and inner wall (endothelium) and smooth muscle of blood vessels. PPARγ is expressed mainly in fat tissue, where it regulates genes involved in fat cell (adipocyte) differentiation, fatty acid uptake and storage, and glucose uptake. It is also found in pancreatic beta cells, vascular endothelium, and macrophages Rosiglitazone is a selective ligand of PPARγ and has no PPARα-binding action. Other drugs bind to PPARα. Rosiglitazone also appears to have an anti-inflammatory effect in addition to its effect on insulin resistance. Nuclear factor kappa-B (NF-κB), a signaling molecule, stimulates the inflammatory pathways. NF-κB inhibitor (IκB) downregulates the inflammatory pathways. When patients take rosiglitazone, NF-κB levels fall and IκB levels increase.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.